Theravance Biopharma (TBPH) Stock Price, News & Analysis

Company Overview

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S. Food and Drug Administration for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

In addition to its marketed respiratory franchise, Theravance Biopharma maintains a diversified pipeline with clinical-stage programs in immunology and rare disease. Its immunology efforts include a gut-selective pan-JAK inhibitor being evaluated for inflammatory bowel diseases, while its rare disease portfolio features a norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. The company leverages internal research capabilities alongside collaborations and partnerships to advance its small-molecule candidates through clinical and regulatory milestones.

Founded in 1998 as part of a respiratory research group of GlaxoSmithKline and later spun out as an independent entity in 2014, Theravance Biopharma is headquartered in South San Francisco, California. It operates research facilities in the Bay Area and maintains corporate offices in Dublin, Ireland, supporting its global clinical programs. The company’s leadership team, under President and Chief Executive Officer Rick E. Winningham, brings deep expertise in pharmaceutical R&D, regulatory affairs and commercial strategy aimed at delivering new therapeutic options to patients worldwide.

Key Stats

• Today's Range: $16.18 to $16.43
• 50-Day Range: $13.78 to $17.23
• 52-Week Range: $9.10 to $21.03
• Volume: 277,610 shs
• Average Volume: 329,516 shs
• Market Capitalization: $843.92 million
• P/E Ratio: 7.44
• Dividend Yield: N/A
• Price Target: $21.83
• Consensus Rating: Moderate Buy

Theravance Biopharma Stock Analysis - MarketRank™

Theravance Biopharma scored higher than 67% of companies evaluated by MarketBeat, and ranked 444th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Theravance Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 strong buy ratings, 2 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Theravance Biopharma has a consensus price target of $21.83, representing about 33.4% upside from its current price of $16.37.

Amount of Analyst Coverage

Theravance Biopharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -73.68%

Earnings Growth

Earnings for Theravance Biopharma are expected to decrease by -73.68% in the coming year, from $0.95 to $0.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Theravance Biopharma is 7.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Theravance Biopharma is 7.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.91.

Price to Book Value per Share Ratio

Theravance Biopharma has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.84% of the float of Theravance Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Theravance Biopharma has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Theravance Biopharma has recently decreased by 0.85%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Theravance Biopharma does not currently pay a dividend.

Dividend Growth

Theravance Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $433,695.00 in company stock.

Percentage Held by Insiders

7.65% of the stock of Theravance Biopharma is held by insiders.

Percentage Held by Institutions

99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/23/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TBPH
• Previous Symbol: NASDAQ:TBPHV
• CIK: 1583107
• Web: www.theravance.com
• Phone: (650) 808-6000
• Fax: N/A
• Employees: 110
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Theravance Biopharma: $21.83
• High Price Target: $27.00
• Low Price Target: $15.00
• Potential Upside/Downside: +33.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.20
• Trailing P/E Ratio: 7.44
• Forward P/E Ratio: 17.23
• P/E Growth: N/A
• Net Income: $105.89 million
• Net Margins: 104.34%
• Pretax Margin: 124.72%
• Return on Equity: 18.84%
• Return on Assets: 10.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.14
• Quick Ratio: 13.14

Sales & Book Value

• Annual Sales: $109.78 million
• Price / Sales: 7.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.64 per share
• Price / Book: 2.90

Miscellaneous

• Outstanding Shares: 51,553,000
• Free Float: 47,609,000
• Market Cap: $843.92 million
• Optionable: Optionable
• Beta: 0.19